🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesA1C target achievement rates — need advice

A1C target achievement rates — need advice

laura_annarbor Mon, Apr 27, 2026 at 4:31 AM 20 replies 793 viewsPage 1 of 4
laura_annarbor
Member
189
890
Dec 2024
Ann Arbor, MI
Apr 27, 2026 at 4:31 AM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very little. The improvement on this class comes from two directions — direct glucose-dependent insulin secretion and glucagon suppression, plus the indirect effect of weight loss on insulin sensitivity — and the second continues after the first has plateaued.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

The question I want answered is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
6 1labquiet_amy, emily_PDX, Dr.SleepRoch and 3 others
Reply Quote Save Share Report
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Apr 27, 2026 at 5:52 AM#2
laura_annarbor said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

Last edited: Apr 27, 2026 at 11:52 AM
5 0ZaraB_AL, JakeSmashed95, NauseaFreeNow and 2 others
Reply Quote Save Share Report
BariatricNurseD
Senior Member
1,678
7,234
Feb 2024
Dallas, TX
Online
Apr 27, 2026 at 7:13 AM#3
laura_annarbor said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.6 (insulin resistant) → Current = 1.0 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

4 24josh_phd_bmore, roxy_nash, tony_orlando and 1 other
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Apr 27, 2026 at 8:34 AM#4
BariatricNurseD said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 39% to 22%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

3 23lori_vegas, Dr.PulmRoch, maya_sedona
Reply Quote Save Share Report
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Apr 27, 2026 at 4:25 PM#5
amsterdam_pete said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

Adding a me-too, because a thread of one person's experience is not much use. The detail I would add is minor and it is already implied above.

Last edited: Apr 27, 2026 at 7:25 PM
2 22LarryQC_SD, wanda_boise
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register